TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. To be 18 years old or older~2. Scheduled for cardiac surgery~3. Treatment will include 72 hours or more of hospital stay~4. Understand enough about the risks and benefits of the study to be able to make an informed decision before agreeing to be in the study~Exclusion Criteria:~1. History of cerebrovascular disease~2. History of skin problems on forehead (skin rashes, acne, allergies, etc.)~3. History of craniofacial surgeries~4. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiac Surgery or Hospitalization (Type: None): Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Node positive Group (experimental group)~  * Primary melanoma \> 2 mm in depth~ * Metastasis must be \> 0.1 mm and detectable by IHC or hematoxylin and eosin (H\&E) to be considered node positive~ * Slides and block for primary and node must be archived in UH dermatopathology~* Node Negative Group (control group)~  * Primary melanoma \> 2 mm in depth~ * A negative sentinel lymph node must be negative by IHC and H\&E~    * No stage IV disease~   * No acral and mucosal histology~   * No history of prior invasive melanoma~   * Underwent primary excision and sentinel lymph node biopsy within 3 months of each other~   * Archived tissue available~ * Slides and block for primary tumor and node biopsy must be archived in University Hospitals Case Medical Center (UH) dermatopathology~Exclusion Criteria:~* Acral and mucosal histology~* Previous diagnosis of invasive melanoma~* previous chemotherapy or immunotherapy~* patients who are found to have stage IV disease during workup

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Low Field Magnetic Stimulation Treatment for Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of bipolar disorder.~* Current depression.~Exclusion Criteria:~* Contraindication for MRI due to metal in eyes/head~* Claustrophobia.~* Inability to lie flat.~* History of brain injury.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active EEP-MRSI treatment (Type: EXPERIMENTAL): 20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
- Sham comparator EP-MRSI (Type: SHAM_COMPARATOR): Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Female, 18+, with evaluable metastatic breast cancer and stable brain metastases~* Must have received definitive radiotherapy~* No evidence, or history of, central nervous system hemorrhage~* Adequate organ and hematological function~Exclusion Criteria:~* Active infection, non-healing wound, or history of any bleeding diathesis or coagulopathy~* Uncontrolled hypertension, congestive heart failure, peripheral vascular disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab / Capecitabine (Type: ACTIVE_COMPARATOR): Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
- Bevacizumab / Docetaxel (Type: ACTIVE_COMPARATOR): Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
- Bevacizumab /Irinotecan (Camptosar®, CPT-11) (Type: ACTIVE_COMPARATOR): CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
- Bevacizumab / Paclitaxel (Type: ACTIVE_COMPARATOR): Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
- Bevacizumab /Vinorelbine Tartrate (Type: ACTIVE_COMPARATOR): Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
- Bevacizumab / Gemcitabine (Type: ACTIVE_COMPARATOR): Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Genu Neurexa Orthosis in Post Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering a first stro(at least 3 months post stroke)~* Cognitive and cooperative ability to follo instructions.~* Patients suffering from paresis of leg muscles resulting in knee hyperextension.~* Ability to walk with or without a walking aid (cane, walker) independently~Exclusion Criteria:~* Cognitive disorders preventing the subject from understanding the trial protocol, signing a consent form or following the researcher's instructions~* Skin disease or wounds at the paretic knee~* Ankle or foot contructure or limited range of motion~* Orthopaedic injury to the paretic or non-paretic limbs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female and Male subjects with known or strong suspicion iof adenoma or carcinoma of the colon after screening of follow-up colonoscopy~* Female and male patients with verified neoplastic lesions~Exclusion Criteria:~* Known or strong suspected porphyria~* Contraindications to colonoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hexaminolevulinate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Patient with the diagnosis of Parkinson's Disease selected for placement of globus pallidus internus (GPi) deep brain stimulator (DBS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GPi DBS (Type: EXPERIMENTAL): Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Validation of MMS Test for Cancer Monitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of colo-rectal cancer~* Clinical diagnosis of stomach cancer~* Suspected diagnosis of melanoma~Exclusion Criteria:~* Colitis ulcerosa~* Morbus Crohn~* Cancer in time period two years before~* Cancer therapy in time period two years before

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MMS test (Type: None): therapy monitoring of patients with colo-rectal or stomach disease or with melanoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Manual Lymph Drainage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* s/p total knee replacement~* Primary diagnosis of osteoarthritis or degenerative joint disease~* Able to read and understand English to consent~* Acceptance of the study protocol procedure~Exclusion Criteria:~* Active infection~* Tumor~* Metastatic or systemic malignancy~* Acute thrombus~* History of pulmonary embolism~* Major cardiac pathology such has angina~* Heart attack or uncompensated congestive heart failure (CHF)~* Body mass index (BMI) \> 40~* Pregnant or lactating women~* Renal dysfunction~* Joint revision~* Hospitalization length of stay less than or greater than 3 days~* Previous knee replacement~* Bilateral knee replacement

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will follow the current standard for post-operative care.
- Experimental (Type: EXPERIMENTAL): Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type I or Type II diabetes mellitus and a glycohemoglobin A1c\<12%~* Minimum of one neuropathic, diabetic ulcer meeting the following criteria: stage III or IV, located on the distal lower extremity, between 1 and 15 square centimeters~* No exposed bone at the ulcer site~* No osteomyelitis affecting the area of the ulcer unless receiving aggressive treatment with expectation of cure~* Adequate arterial circulation to the foot~* New ulcers must be meet the following criteria: full-thickness ulcer (Stage III or IV), located on feet or ankles, no exposed bone at the ulcer site, no osteomyelitis affecting the area of the ulcer unless receiving aggressive treatment with expectation of cure~* Recurrent ulcers must meet the following criteria: stage II, III or IV, no exposed bone at the ulcer site, no osteomyelitis affecting the area of the ulcer unless receiving aggressive treatment with expectation of cure~* Females must be postmenopausal, surgically incapable of childbearing, or using an acceptable method of birth control and have negative pregnancy test~Exclusion Criteria:~* Hypersensitivity to REGRANEX® Gel or one of its components~* Presence of more than two full-thickness diabetic ulcers on either lower extremity~* presence of an active systemic or local cancer or tumor of any kind~* Use of topical antibiotics, antiseptics, enzymatic debriders, or any other agents on the selected ulcers, within the seven days preceding randomization~* Active rheumatic or collagen vascular disease or pre-existing conditions or diseases which may interfere with the evaluation of safety or efficacy of Regranex~* Systemic corticosteroid maintenance therapy, immunosuppressive or chemotherapeutic agents within 14 days prior to first study drug application or are likely to receive one of these therapies during study participation~* Radiation therapy that included the distal lower extremity, at any time in patient's life~* Charcot deformity (rocker bottom foot)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-SOPHrology Cancer Patients' anxieTY Report

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patient performing at least one session of sophrology in the Lucien Neuwirth Cancer Institute~Exclusion Criteria:~* Protected patient (according to the law),~* Patient with incapacity to complete questionnaires,~* Patient with incapacity to perform sophrologic movements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cancer patients performing sophrology sessions (Type: None): Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (\>18 years) within 24 hours of admission to intensive care unit with proven or suspected COVID-19 infection. For the purpose of this study, intensive care unit is defined as a facility that allow continuous monitoring of vital functions and oxygen administration . It is expected that most patients will have rtPCR test known within 24 hours of admission to hospital. Nonetheless, if this is not the case (eg. due to overloaded lab facility, lack of supplies) it is possible to randomise a patient based on a strong clinical suspicion of SARS-Cov-2 infection. In case COVID-19 is not confirmed in retrospect, experimental therapy is withdrawn and the study subject is withdrawn from per protocol analysis of the primary and secondary outcomes, but remains in intention-to-treat cohort for the analysis of safety.~Exclusion Criteria:~* symptoms of febrile disease for ≥1 week, pregnancy, treatment limitations in place or moribund patients, allergy or intolerance of any study treatment, incl. long QT syndromes, myasthenia gravis, allergies or known deficiency of glucose-6-phosphate dehydrogenase, participation in another outcome-based interventional trial within last 30 days, patients taking Hydrochloroquine for other indication than COVID-19.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HC-A group (Type: EXPERIMENTAL): * Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and 500 mg of Azithromycin once in 24 hours (with the first dose of hydrochloroquine)~* Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval 250 mg of Azithromycin once in 24 hours (with the first daily dose of hydrochloroquine)
- HC group (Type: ACTIVE_COMPARATOR): * Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)~* Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)
- C group (Type: PLACEBO_COMPARATOR): • Day 1-5: Patients receive two doses of placebo in 12 hours interval and 1 extra dose of placebo once in 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Helmet CPAP Versus HFNC in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (all of the following):~1. Age ≥ 18 years~2. Sars-Cov-2 found in the upper or lower respiratory tract by PCR during the current disease episode~3. Peripheral oxygen saturation (SpO2) \< 92 % despite conventional low-flow oxygen therapy of at least 6 L /min for at least 15 min~4. A decision to initiate HFNC or Helmet CPAP by the attending ward physician~5. The patient has given written informed consent to participate.~Exclusion Criteria (any of the following):~1. Need for direct admission to the intensive care unit for mechanical ventilation~2. Unconsciousness or drowsiness~3. Pneumothorax~4. Carbon dioxide pressure (pCO2) \> 6 kPa in venous blood gas (VBG)~5. Underlying chronic obstructive pulmonary disease stage III-IV~6. A decision not to participate~7. Inability to comprehend the study content and give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Helmet CPAP (Type: ACTIVE_COMPARATOR): Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
- HFNC (Type: ACTIVE_COMPARATOR): High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Oocyte donors~* Ages between 21 and 33~* Normal baseline serum FSH \< 10mIU/mL~Exclusion Criteria:~* Hypothalamic dysfunction~* Smokers~* Baseline serum FSH ≥ 10mIU/mL

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 33 Years
- Healthy Volunteers: t

Study Arms:
- GnRH agonist trigger (Type: EXPERIMENTAL): Induction of oocyte maturation with GnRH agonist
- hCG trigger (Type: ACTIVE_COMPARATOR): Induction of oocyte maturation with hCG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues